Amaero International, an ASX-listed company with manufacturing and corporate headquarters located in Tennessee, USA, has updated its financial guidance, revising key projections for capital expenditures and EBITDA breakeven timelines.
In its latest Investor Presentation dated 14 August 2024, Amaero has adjusted its estimated capital expenditures for the three-year period from FY2024 to FY2026 to $71.5 million, up from the previous estimate of $71.3 million.
The adjustment reflects a deferral of $7.4 million in expenditures originally budgeted for FY2024, which will now be allocated to FY2025.
For FY2024, actual expenditures totalled $11.2 million, significantly lower than the earlier estimate of $18.6 million.
The company has also revised its EBITDA breakeven estimate. Previously projected for calendar year 2025, Amaero now expects to achieve EBITDA breakeven in FY2026.
This delay is attributed to the need for the company to complete the qualification of its C103 product by the end of the second quarter of FY2025.
Additionally, the updated estimate considers revenue from offtake and preferred supplier agreements, scaling production of the first atomizer throughout the calendar year 2025, and commercial demand for isostatic powder pressing (IPP) components.
Amaero’s Chairman and CEO, Hank Holland, will provide further insights during an investor briefing scheduled for 11:30 am AEST today, where he will discuss the company’s anticipated milestones for FY2025 and address any questions from stakeholders.
